LLY - Eli Lilly and Company
85.73 0.00 (0.00%)
After hours: 6:04PM EDT
| Previous Close | 86.06 |
| Open | 86.33 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 85.52 - 86.56 |
| 52 Week Range | 64.18 - 89.09 |
| Volume | 4,002,151 |
| Avg. Volume | 3,537,841 |
| Market Cap | 89.77B |
| Beta | 0.15 |
| PE Ratio (TTM) | 37.10 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.42%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- CNBC Videos•yesterday
This hot trade is about to get even hotter: Trader
The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.
- Zacks•6 hours ago
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
- Market Realist•12 hours ago
Behind Eli Lilly’s Performance in 3Q17
LLY stock rose ~4.5% in 3Q17 and has risen 17.7% YTD (year-to-date) as of October 16.
- Market Realist•12 hours ago
Understanding Eli Lilly’s Position in Neurology Drugs after 1H17
In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16.
- Market Realist•13 hours ago
Inside Eli Lilly’s Endocrinology Franchise Positioned after 1H17
In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16.
- Motley Fool•14 hours ago
10 Stunning Numbers You Need to Know About Breast Cancer
There's more good news than you might think.
Markit•14 hours agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Zacks•15 hours ago
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
- Market Realist•15 hours ago
Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018
In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
- Reuters•16 hours ago
Eli Lilly to collaborate with Germany's CureVac on cancer vaccines
U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million (45 million euros).
- Reuters•yesterday
Trump favors ex-pharma executive Azar for health secretary -Politico
U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ...
- Market Realist•yesterday
How Eli Lilly’s Taltz Is Positioned after 1H17
In 1H17, Eli Lilly’s (LLY) Taltz reported revenues of ~$235.3 million, compared with $19.3 million in 1H16.
- Forbes•2 days ago
The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
- Market Realist•2 days ago
This Could Be Eli Lilly’s Long-Term Growth Driver
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
- Market Realist•3 days ago
Inside Eli Lilly’s Oncology Portfolio: Key Updates
In 1H17, Eli Lilly’s (LLY) Alimta reported revenues of around $1.0 billion, compared with $1.2 billion in 1H16.
- Market Realist•3 days ago
Gauging Eli Lilly’s Position with Cyramza after 1H17
In 1H17, Eli Lilly’s (LLY) Cyramza reported revenues of around $357.5 million, compared with $278.0 million in 1H16.
- Zacks•5 days ago
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
The pharma/biotech sector has a number of things going in its favor.
- Market Realist•5 days ago
This Could Boost Eli Lilly’s Revenue Growth in 2018
In September, the FDA approved Eli Lilly's (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+.
- Market Realist•5 days ago
How Eli Lilly Is Positioned after 1H17
In 1H17, Eli Lilly (LLY) generated revenues of around $11.0 billion, compared with $10.3 billion in 1H16.
- Market Realist•5 days ago
Behind Eli Lilly’s October Analyst Recommendations
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
- Zacks•5 days ago
Cancer Space Update: Lung & Breast Cancer Studies in Focus
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
- Zacks•6 days ago
Lilly's Verzenio Gets Priority Review in First-Line Setting
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
- Zacks•6 days ago
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
- Zacks•7 days ago
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.
